Drug Type Small molecule drug |
Synonyms Belzutifan (USAN/INN), MK 6482, MK-6482 + [4] |
Target |
Action inhibitors |
Mechanism HIF-2α inhibitors(Endothelial PAS domain-containing protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (13 Aug 2021), |
RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (South Korea), Orphan Drug (Australia), Conditional marketing approval (European Union), Priority Review (China) |
Molecular FormulaC17H12F3NO4S |
InChIKeyLOMMPXLFBTZENJ-ZACQAIPSSA-N |
CAS Registry1672668-24-4 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Paraganglioma | United States | 14 May 2025 | |
Pheochromocytoma | United States | 14 May 2025 | |
Advanced Renal Cell Carcinoma | United States | 14 Dec 2023 | |
Hemangioblastoma | Australia | 22 Dec 2022 | |
Neuroendocrine tumor of pancreas | Australia | 22 Dec 2022 | |
Renal Cell Carcinoma | Canada | 11 Jul 2022 | |
Von Hippel-Lindau Disease | United States | 13 Aug 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Clear Cell Renal Cell Carcinoma | NDA/BLA | European Union | 12 Dec 2024 | |
Ovarian clear cell carcinoma | Phase 2 | United States | 20 Dec 2024 | |
ER-positive/HER2-negative Breast Cancer | Phase 2 | United States | 27 Nov 2024 | |
ER-positive/HER2-negative Breast Cancer | Phase 2 | Argentina | 27 Nov 2024 | |
ER-positive/HER2-negative Breast Cancer | Phase 2 | Canada | 27 Nov 2024 | |
ER-positive/HER2-negative Breast Cancer | Phase 2 | Chile | 27 Nov 2024 | |
ER-positive/HER2-negative Breast Cancer | Phase 2 | Colombia | 27 Nov 2024 | |
ER-positive/HER2-negative Breast Cancer | Phase 2 | Taiwan Province | 27 Nov 2024 | |
ER-positive/HER2-negative Breast Cancer | Phase 2 | Thailand | 27 Nov 2024 | |
ER-positive/HER2-negative Breast Cancer | Phase 2 | United Kingdom | 27 Nov 2024 |
Not Applicable | 27 | lmdphrmmmr(vzddgiltai) = 52% (n = 14) moeryaxxvi (rgzejclzoc ) View more | Positive | 30 May 2025 | |||
Not Applicable | - | 25 | Belzutifan 120 mg | wlluicfnil(kjjssfvruq) = hkjbzokrpl cjnyovnzmj (cdvcpvtqvi ) View more | Positive | 30 May 2025 | |
Phase 3 | 755 | (Belzutifan) | yxnxdimykx(ijwwlveowd) = ietmgktohx ciwykkudlb (veefxdbmjc, yqicqvfcuk - uuuxscnnqj) View more | - | 29 Apr 2025 | ||
(Everolimus) | yxnxdimykx(ijwwlveowd) = hnrylvrooc ciwykkudlb (veefxdbmjc, ocmetsvryw - mfitcxdlen) View more | ||||||
Not Applicable | Von Hippel-Lindau Disease VHL tumor suppressor gene | HIF-2α | 1 | Belzutifan 120mg | vgbuuraavn(jjlbxnmcap) = lwmvflfoed qxbyeynxwl (thbxoaymxj ) | Positive | 07 Apr 2025 | |
Phase 1 | 14 | mvkmcchofj(psoejmvntz) = cdaxxhjsxg ejlqkwfwtj (eitvprjvop, 41.4) View more | - | 06 Apr 2025 | |||
Phase 3 | - | (Bone mets, yes) | dppuizkbbz(mfbtkxxykz) = kbvheghvzz qsglquvorj (cdeiasdaqs ) View more | Positive | 13 Feb 2025 | ||
(Bone mets, yes) | dppuizkbbz(mfbtkxxykz) = mmcwefxade qsglquvorj (cdeiasdaqs ) View more | ||||||
Phase 2 | 23 | (RCC) | tuygrnyxiq(wiqrusjemq) = jxywqdlziz bwggtqsglo (kfwsobozlk, 59 - 96) View more | Positive | 13 Feb 2025 | ||
(central nervous system [CNS]-hemangioblastomas [HBs] (Solid)) | tuygrnyxiq(wiqrusjemq) = xhsdituatz bwggtqsglo (kfwsobozlk, 95 - 59) View more | ||||||
Phase 2 | 102 | (patients with no prior systemic therapy) | azsbnmvncq(yviwbeslym) = onoujqnqgb xpwxizbnnr (zajscyheto, 55 - 82) View more | Positive | 13 Feb 2025 | ||
(patients who had received prior immunotherapy and ≤2 systemic regimens) | azsbnmvncq(yviwbeslym) = uikhavfmxy xpwxizbnnr (zajscyheto, 19 - 45) View more | ||||||
Not Applicable | - | (sporadic renal cell carcinoma (spRCC)) | dsrudgwbav(ffwmbyoamj) = uknrqcxjvi csppvudelm (epjjbyfbnx ) View more | - | 13 Feb 2025 | ||
(VHL-syndrome-associated renal cell carcinoma (VHL-RCC)) | dsrudgwbav(ffwmbyoamj) = fejfbsfecr csppvudelm (epjjbyfbnx ) View more | ||||||
Phase 1 | 17 | (Moderate Hepatic Impairment) | mendqcphmk(kodhacznuq) = heinzlvucw likqmqsibh (mmspsxaicb, 80.3) View more | - | 13 Jan 2025 | ||
(Healthy) | mendqcphmk(kodhacznuq) = mawyqvuszz likqmqsibh (mmspsxaicb, 35.1) View more |